Table 3

Long-Term Outcomes in Published Studies of DES Versus BMS in SVG Lesions

First Author (Ref. #) (Year)Mean Follow-Up (Months)BMS (n)DES (n)DES TypeDeath (%)MI (%)TVR (%)
BMSDESp ValueBMSDESp ValueBMSDESp Value
Retrospective studies
 Minutello (14) (2007)205059SES126.80.512.06.80.373615.30.01
 Bansal (15) (2008)33723795% SES22190.68NRNRNR42350.47
 Gioia (16) (2008)2411910645% SES, 46% PES, 8% tacrolimus-eluting660.9120.814140.9
 Ramana (17) (2008)34170141SES1260.05950.1916130.52
 Applegate (18) (2008)24747491% SES, 9% PES560.7915110.4017100.18
 Assali (19) (2008)244368SES, PES4.72.90.678.80.927.910.30.02
 van Twisk (20) (2008)48128122SES, PES2722.5NS11.17.6NS3118.4NS
 Guo (21) (2008)124750SES, PES02.00.324.200.3025.5100.05
 Lozano (22) (2009)30 median11498NRNRNRNRNRNRNR13170.49
 Shishehbor (23) (2009)35 median349217NR1613NS67NS613NS
 Goswami (24) (2009)369528484% SES, 16% PES14.618.6NS3.49.6NS10.610.6NS
 Brodie (25) (2009)2434378559% SES, 38% PES, 3% both14.78.20.00511.311.90.0616.918.30.86
 Latib (26) (2010)24131127SES, PES7.88.70.999.46.30.5024.219.70.47
 Baldwin (27) (2010)3619220363% SES, 30% PES, 7% both18.116.80.7318.616.10.3922.223.00.88
Prospective studies
 Jeger (28) (2008)18133465% SES, 35% PESNRNRNR061.046180.045
 RRISC (2,3) (2006, 2007)32 median3738SES029<0.0015180.1538340.74
 SOS (4) (present)35 median3941PES13240.1946170.0149220.03

DES = drug-eluting stent(s); MI = myocardial infarction; NR = not reported; NS = not significant; SES = sirolimus-eluting stent(s); TVR = target vessel revascularization; other abbreviations as in Tables 1 and 2.